Danish Cancer Society Research Center, Copenhagen, Denmark.
Acta Oncol. 2013 May;52(4):831-6. doi: 10.3109/0284186X.2012.702922. Epub 2012 Jul 19.
The incidence of prostate cancer (PC) has increased during the last 15 years in Denmark, whereas the mortality has remained largely unchanged. This register study aimed to investigate the trends in PC incidence and mortality in Denmark 1978-2009 with special focus on the recent 15 years.
From the nationwide Danish Cancer Registry and Register of Causes of Death, we obtained information on all cases of PC and all deaths in Denmark during 1978-2009. Age-standardised (World Standard Population) incidence and mortality rates were computed for five-year calendar periods (1978-2007) and a two-year calendar period (2008-2009). Trends in incidence rates were estimated for specific age groups, birth cohorts, and clinical stage.
The age-standardised incidence rate of PC increased from 29.2 per 100,000 person-years in 1978-1982 to 76.2 per 100,000 person-years in 2008-2009. The incidence increase began primarily in the mid-1990s. The corresponding mortality rates of PC remained largely unchanged during the entire study period; around 19 per 100,000 person-years. The incidence increase was most pronounced among men aged 60 + years. A clear pattern was also seen for selected birth cohorts, with increasing incidence rates among the youngest cohorts, and the highest relative increase in age-specific incidence rates was seen among men born between 1943 and 1947. The distribution of stage changed from 1998, with an increasing proportion of PC patients with localised disease.
The observed increase in PC incidence during the period 1993-2009 in Denmark may be attributed primarily to increasing unsystematic use of prostate specific antigen (PSA) testing. The mortality rates remained stable during the same period suggesting that there is not yet any major influence of intensified PSA screening and more frequent use of curatively intended therapy on the overall prognosis of PC.
在过去的 15 年中,丹麦的前列腺癌(PC)发病率有所增加,而死亡率基本保持不变。本研究旨在调查 1978-2009 年丹麦 PC 的发病率和死亡率趋势,特别关注最近的 15 年。
从全国性的丹麦癌症登记处和死因登记处,我们获得了 1978-2009 年期间丹麦所有 PC 病例和所有死亡的信息。计算了五个五年期(1978-2007 年)和两个两年期(2008-2009 年)的年龄标准化(世界标准人口)发病率和死亡率。对特定年龄组、出生队列和临床分期的发病率趋势进行了估计。
1978-1982 年至 2008-2009 年,PC 的年龄标准化发病率从每 100,000 人年 29.2 例上升至每 100,000 人年 76.2 例。发病率的上升始于 20 世纪 90 年代中期。整个研究期间,PC 的死亡率基本保持不变,约为每 100,000 人年 19 例。发病率的上升在 60 岁以上的男性中最为明显。在特定的出生队列中也出现了明显的模式,最年轻的队列发病率上升,年龄特异性发病率的相对上升幅度最大,在 1943 年至 1947 年出生的男性中。从 1998 年开始,疾病分期的分布发生了变化,局部疾病患者的比例增加。
在 1993-2009 年期间,丹麦观察到的 PC 发病率增加可能主要归因于前列腺特异性抗原(PSA)检测的非系统性使用增加。同期死亡率保持稳定,这表明 PSA 筛查的强化和更频繁地使用有治愈意图的治疗对 PC 的总体预后尚未产生重大影响。